JH
Insider
Jeffrey William Henderson
DirectorJeffrey William Henderson (Director) filed 5 Form 4 reports in the past 24 months (1 purchase, 4 sales), most often in Halozyme Therapeutics, Inc. (HALO). Across 1 priced purchase filing, the average 21-session return was -1.7% from execution and -1.7% from disclosure (delay-adjusted; derived). The largest single filing was $500K of HALO (10,000 sh × $50.01, as filed), executed Jan 6 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-1.7%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-1.7%
same 1 filings, from disclosure
Filings, ttm
5
1 buys · 4 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.6M
shares × price, as filed
Last traded
Apr 28 2025
Filed Apr 28 2025
Median ADV $214.5M across their filed names
Open performance→Volume by month
Buys $350K
Sells $1.3M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
5 filings
Sector per market data · by filing · past 24 months
Most traded names
HALORecent filings
HALOSALE
Halozyme Therapeutics, Inc.
View filing →
$259K4,297 sh × $60.34
Exec Apr 28 2025
Filed Apr 28 2025 · 5:30 PM ET HALOSALE Halozyme Therapeutics, Inc. View filing → $293K
5,000 sh across 2 lots
Exec Mar 3 2025
Filed Mar 3 2025 · 5:30 PM ET BDXPURCHASE Becton, Dickinson and Company View filing → $350K
1,500 sh × $233.62
Exec Feb 10 2025
Filed Feb 10 2025 · 5:30 PM ET HALOSALE Halozyme Therapeutics, Inc. View filing → $220K
3,900 sh × $56.41
Exec Feb 3 2025
Filed Feb 4 2025 · 5:30 PM ET HALOSALE Halozyme Therapeutics, Inc. View filing → $500K
10,000 sh × $50.01
Exec Jan 6 2025
Filed Jan 7 2025 · 5:30 PM ET